Nasdaq · Healthcare
Artiva Biotherapeutics, Inc. (ARTV)
As-reported financials and recent SEC filings for Artiva Biotherapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$0
Net income
$-83.9M
Net margin
—
Diluted EPS
$-3.43
ROE
-76.3%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2024 |
|---|---|---|---|
| Revenue | $0 | $251,000 | $33.5M |
| Gross profit | — | — | — |
| Operating income | $-89.8M | $-67.3M | $-30.7M |
| Net income | $-83.9M | $-65.4M | $-28.7M |
| Diluted EPS | $-3.43 | $-2.90 | $-1.28 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-29
View on EDGAR →42026-06-16
View on EDGAR →SCHEDULE 13D/A2026-06-15
View on EDGAR →42026-06-11
View on EDGAR →SCHEDULE 13D/A2026-05-28
View on EDGAR →42026-05-28
View on EDGAR →42026-05-19
View on EDGAR →42026-05-19
View on EDGAR →Largest Healthcare peers
Go deeper on ARTV
Search Artiva Biotherapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.